PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
28378895-5	2018	RESULTS: Extended natalizumab dose schedule promoted an increase of CD49d molecules per cell surface and a reduction of CD49d RO levels.	ro	126-128	integrin subunit alpha 4	Homo sapiens	120-125
28378895-8	2018	CONCLUSIONS: Following up CD49d RO levels with a well-regulated monitoring work scheme is crucial to further identify over-/under-treated patients and to define a safe, personalized natalizumab regimen.	ro	32-34	integrin subunit alpha 4	Homo sapiens	26-31
28439079-5	2017	We observed that transfection with an ITGA4-mRNA construct bearing a conventional cap analogue (7-methylguanosine) failed to produce ITGA4 protein, but exogenous ITGA4-mRNA was detected in transfected MSCs.	7-methylguanosine	96-113	integrin subunit alpha 4	Homo sapiens	38-43
28578393-2	2017	MTI-101 is a first-in-class peptidomimetic that binds a CD44/ITGA4 containing complex and triggers necrotic cell death in multiple myeloma cell lines.	MTI-101	0-7	integrin subunit alpha 4	Homo sapiens	61-66
27697994-6	2017	Cerdulatinib induced apoptosis of CLL cells, in a time- and concentration-dependent manner, and particularly in IGHV-unmutated samples with greater BCR signaling capacity and response to IL4, or samples expressing higher levels of sIgM, CD49d+, or ZAP70+ Cerdulatinib overcame anti-IgM, IL4/CD40L, or NLC-mediated protection by preventing upregulation of MCL-1 and BCL-XL; however, BCL-2 expression was unaffected.	4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide	0-12	integrin subunit alpha 4	Homo sapiens	237-242
29117236-0	2017	Effects of CD49d-targeted antisense-oligonucleotide on alpha4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies.	Oligonucleotides	36-51	integrin subunit alpha 4	Homo sapiens	11-16
28646624-6	2017	Higher BAP test values were found in patients expressing CD49d (P=.01) and with more advanced clinical stage (P=.004).	benzylaminopurine	7-10	integrin subunit alpha 4	Homo sapiens	57-62
28321213-5	2017	Upon retinoic acid (RA) exposure, CD161+ T cells were more enriched for CCR9+ and integrin alpha4+beta7+ cells than CD161- T cells.	Tretinoin	5-18	integrin subunit alpha 4	Homo sapiens	82-97
28321213-5	2017	Upon retinoic acid (RA) exposure, CD161+ T cells were more enriched for CCR9+ and integrin alpha4+beta7+ cells than CD161- T cells.	Tretinoin	20-22	integrin subunit alpha 4	Homo sapiens	82-97
27496090-4	2016	CD49d expression up to month three after NTZ-W was related to MS activity in CD45+CD8+ at the end of the study.	ntz-w	41-46	integrin subunit alpha 4	Homo sapiens	0-5
27083540-6	2016	High-cell surface expression of integrin alpha4 enabled the use of a fluorescence-activated cell sorter (FACS) approach for TBPC isolation from the human smooth chorion (n = 6 lines).	2-(4-tert-butylphenoxy)cyclohexanol	124-128	integrin subunit alpha 4	Homo sapiens	32-47
26478898-0	2015	Dimethyl fumarate inhibits integrin alpha4 expression in multiple sclerosis models.	Dimethyl Fumarate	0-17	integrin subunit alpha 4	Homo sapiens	27-42
26880989-6	2016	Knockdown of integrin alpha 4 by integrin alpha 4 siRNA (siITGA4) treatment increased BM-MSC migration by upregulation of ROCK1, Rac1/2/3, and matrix metalloproteinase-2 regardless of oxygen tension.	Oxygen	184-190	integrin subunit alpha 4	Homo sapiens	13-29
26880989-6	2016	Knockdown of integrin alpha 4 by integrin alpha 4 siRNA (siITGA4) treatment increased BM-MSC migration by upregulation of ROCK1, Rac1/2/3, and matrix metalloproteinase-2 regardless of oxygen tension.	Oxygen	184-190	integrin subunit alpha 4	Homo sapiens	33-49
23647062-5	2014	Consistently, we found that bortezomib treatment down-regulated the surface expression of CD49d and CD44, which mediate the adhesion of cHL cells to HL-AFs, and of CD54 and CD40, which mediate the adhesion to CD40L+ rosetting T-cells.	Bortezomib	28-38	integrin subunit alpha 4	Homo sapiens	90-95
24516016-7	2014	Decrease in OS at 5 and 10 years among CD49d+ patients was 7% and 23% (decrease in TFS, 26% and 25%, respectively).	Osmium	12-14	integrin subunit alpha 4	Homo sapiens	39-44
24516016-8	2014	Pooled HR of CD49d for OS was 2.5 (2.3 for TFS) in univariate analysis.	Osmium	23-25	integrin subunit alpha 4	Homo sapiens	13-18
25550552-6	2015	The expression of migration-related integrins, including integrin beta1 and integrin alpha4 was significantly reduced in response to DF-A treatment.	4,6-dimethoxy-9-(4-methoxybenzyl)-8-(2-(4-methoxyphenyl)ethyl)-9H-xanthene-2,3,5-triol	133-137	integrin subunit alpha 4	Homo sapiens	76-91
25503138-11	2014	Cisplatin induced a dramatic alteration in the integrin expression pattern by up-regulating integrin alpha4, alphav, beta1, and beta5 which were previously reported to increase cell motility, while it had no effect on integrin alpha5, and beta3.	Cisplatin	0-9	integrin subunit alpha 4	Homo sapiens	92-107
25239835-1	2014	OBJECTIVE: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the alpha subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS).	Oligonucleotides	81-96	integrin subunit alpha 4	Homo sapiens	140-145
24903479-0	2014	Effects of the small-molecule inhibitor of integrin alpha4, TBC3486, on pre-B-ALL cells.	3-(1,3-benzodioxol-5-yl)-3-((((-1-((bis(2-thienylmethyl)amino)carbonyl)pentyl)amino)carbonyl)amino)propanoic acid	60-67	integrin subunit alpha 4	Homo sapiens	43-58
24824789-4	2014	Resistance to ATRA-induced cell cycle arrest at the G1/S phase transition in knockdown cells was accompanied by retained expression of ITGA4 (CD49d) and decreased induction of ITGAX (CD11c).	Tretinoin	14-18	integrin subunit alpha 4	Homo sapiens	135-140
24824789-4	2014	Resistance to ATRA-induced cell cycle arrest at the G1/S phase transition in knockdown cells was accompanied by retained expression of ITGA4 (CD49d) and decreased induction of ITGAX (CD11c).	Tretinoin	14-18	integrin subunit alpha 4	Homo sapiens	142-147
24068493-4	2013	Consistently, CD49d expression was recovered in CD49d(-) hypermethylated CLL cells upon in vitro treatment with the hypomethylating agent 5-aza-2"-deoxycytidine.	Decitabine	138-160	integrin subunit alpha 4	Homo sapiens	14-19
24376763-8	2013	Furthermore, we demonstrate that CLL cell adhesion to EC and VLA-4 (CD49d) resulted in the phosphorylation of Akt, which was sensitive to inhibition by idelalisib.	idelalisib	152-162	integrin subunit alpha 4	Homo sapiens	68-73
24068493-4	2013	Consistently, CD49d expression was recovered in CD49d(-) hypermethylated CLL cells upon in vitro treatment with the hypomethylating agent 5-aza-2"-deoxycytidine.	Decitabine	138-160	integrin subunit alpha 4	Homo sapiens	48-53
22050952-8	2012	In contrast, in eight patients (16%) there was an early recovery of CD49d expression to pre-treatment levels related to NABs development.	nabs	120-124	integrin subunit alpha 4	Homo sapiens	68-73
22318983-0	2013	Integrin alpha4 impacts on differential adhesion of preadipocytes and stem cells on synthetic polymers.	Polymers	94-102	integrin subunit alpha 4	Homo sapiens	0-15
20937409-8	2011	Internalization and recovery of Tspan8 in early endosomes is further promoted by the recruitment of CD49d such that only in PMA-activated cells a Tspan8-INS2-CD49d-clathrin complex is recovered in cholesterol-depletion-resistant membrane microdomains.	Cholesterol	197-208	integrin subunit alpha 4	Homo sapiens	100-105
22159714-8	2012	Greater doxorubicin resistance was             exhibited by the CD49d+/high population, compared with the CD49d-/low population.	Doxorubicin	8-19	integrin subunit alpha 4	Homo sapiens	64-69
21131132-9	2011	Expression of CD11a (p < 0.05), CD18 (p < 0.05) and CD97 (p < 0.01) on the granulocytes were significantly lower in the NAC treated group, similarly to lymphocyte CD 49d (p < 0.05) and monocyte CD 49d (p < 0.01) and CD 97 (p < 0.05) expression.	Acetylcysteine	129-132	integrin subunit alpha 4	Homo sapiens	172-178
21131132-9	2011	Expression of CD11a (p < 0.05), CD18 (p < 0.05) and CD97 (p < 0.01) on the granulocytes were significantly lower in the NAC treated group, similarly to lymphocyte CD 49d (p < 0.05) and monocyte CD 49d (p < 0.01) and CD 97 (p < 0.05) expression.	Acetylcysteine	129-132	integrin subunit alpha 4	Homo sapiens	206-212
20937409-8	2011	Internalization and recovery of Tspan8 in early endosomes is further promoted by the recruitment of CD49d such that only in PMA-activated cells a Tspan8-INS2-CD49d-clathrin complex is recovered in cholesterol-depletion-resistant membrane microdomains.	Cholesterol	197-208	integrin subunit alpha 4	Homo sapiens	158-163
18850009-4	2009	shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184 significantly reversed CAM-DR of myeloma cells to bortezomib, vincristine, doxorubicin and dexamethasone.	Bortezomib	120-130	integrin subunit alpha 4	Homo sapiens	28-33
20691129-6	2010	After the CHO-enriched meal, there was a time-dependent increased expression of CD162, CD49d, CD11a and CD54 on PBMC that returned to basal values after 8-10 h. These changes were significantly greater than the ones observed after the consumption of the monounsaturated fat- and the saturated fat-enriched meals and were more evident in lymphocytes than in monocytes.	CAV protocol	10-13	integrin subunit alpha 4	Homo sapiens	87-92
21033217-3	2010	METHODS: The methylation status of ITGA4, SFRP2 and p16 promoters in bisulfite-modified stool DNA was investigated in a blinded manner with methylation specific PCR (MSP) from 31 endoscopically diagnosed healthy controls, 25 patients with adenomas and 30 patients with CRC.	hydrogen sulfite	69-78	integrin subunit alpha 4	Homo sapiens	35-40
19576658-6	2010	Interestingly, C6-ceramide inhibited the phosphorylation of CD29 induced by MEM101A treatment and down-regulated surface levels of CD29, CD98, and CD147, as well as CD49d.	N-caproylsphingosine	15-26	integrin subunit alpha 4	Homo sapiens	165-170
19655168-6	2010	In addition, the downregulated expression of integrin alpha4 in CC cells with hypermethylation of the integrin alpha4 gene was restored by treatment with 5-aza-2"-deoxycytidine, a DNA methyltransferase inhibitor.	Decitabine	154-176	integrin subunit alpha 4	Homo sapiens	45-60
19655168-6	2010	In addition, the downregulated expression of integrin alpha4 in CC cells with hypermethylation of the integrin alpha4 gene was restored by treatment with 5-aza-2"-deoxycytidine, a DNA methyltransferase inhibitor.	Decitabine	154-176	integrin subunit alpha 4	Homo sapiens	102-117
18850009-4	2009	shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184 significantly reversed CAM-DR of myeloma cells to bortezomib, vincristine, doxorubicin and dexamethasone.	Vincristine	132-143	integrin subunit alpha 4	Homo sapiens	28-33
18850009-4	2009	shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184 significantly reversed CAM-DR of myeloma cells to bortezomib, vincristine, doxorubicin and dexamethasone.	Doxorubicin	145-156	integrin subunit alpha 4	Homo sapiens	28-33
18850009-4	2009	shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184 significantly reversed CAM-DR of myeloma cells to bortezomib, vincristine, doxorubicin and dexamethasone.	Dexamethasone	161-174	integrin subunit alpha 4	Homo sapiens	28-33
18850009-6	2009	Bortezomib was relatively resistant to CAM-DR because of its ability to specifically downregulate CD49d expression.	Bortezomib	0-10	integrin subunit alpha 4	Homo sapiens	98-103
18240216-5	2008	RESULTS: Inhibiting MEK/ERK with U0126 significantly reduced expression of a cohort of proadhesive and procontractile proteins that normally are overexpressed by scleroderma fibroblasts, including integrin alpha4 and integrin beta1.	U 0126	33-38	integrin subunit alpha 4	Homo sapiens	197-212
18680729-5	2008	This study provides evidence that in a scintillation proximity assay levocabastine (IC(50) 406 microM), but not the first-generation antihistamine chlorpheniramine, displaced (125)I-FN binding to human integrin alpha(4)beta(1) and, in flow cytometry analysis, levocabastine antagonized the binding of a primary antibody to integrin alpha(4) expressed on the Jurkat cell surface.	levocabastine	69-82	integrin subunit alpha 4	Homo sapiens	202-219
18799080-8	2008	PGE1 treatment resulted in decrease of both CD11a (+) (67.72+/-3.34%, p<0.0001) and CD49d (+) lymphocytes (65.32+/-1.62%, p<0.0001).	Alprostadil	0-4	integrin subunit alpha 4	Homo sapiens	87-92
18522232-8	2008	In addition, flow cytometry analysis showed that SP cells had high expression of CD13, CD29, CD44, CD46, CD49b, CD49c, CD49e, CD59, CD140a, and CD166 but low expression of CD 49d, and CD51.	sp	49-51	integrin subunit alpha 4	Homo sapiens	172-178
12818364-7	2003	L-NAME induced a discrete increase in the expression of CD49d (VLA-4, 25.3+/-4.8%), but not CD11b, on the neutrophil cell surface, as detected by flow cytometry.	NG-Nitroarginine Methyl Ester	0-6	integrin subunit alpha 4	Homo sapiens	56-61
17060684-7	2006	Histamine decreased CD49d positive cells by 74% while increasing CD31 positive cells by 53% as compared to controls.	Histamine	0-9	integrin subunit alpha 4	Homo sapiens	20-25
17060684-11	2006	In summary, this study demonstrated that histamine inhibited HL-60 cell growth and regulated immunophenotypes of CD49d and CD31.	Histamine	41-50	integrin subunit alpha 4	Homo sapiens	113-118
14525968-7	2004	Inhibition of CD49d expression was equally inhibited by ATL146e, added before or after TNF priming, and was reversed by incubation with the A(2A)AR-selective antagonist 4-[2-[7-amino-2-(2-furyl) (1, 2, 4)triazolo(2,3-a) (1, 3, 5)triazin-5-yl-amino]ethyl]-phenol (ZM241385; 100 nM).	ZM 241385	169-261	integrin subunit alpha 4	Homo sapiens	14-19
14525968-7	2004	Inhibition of CD49d expression was equally inhibited by ATL146e, added before or after TNF priming, and was reversed by incubation with the A(2A)AR-selective antagonist 4-[2-[7-amino-2-(2-furyl) (1, 2, 4)triazolo(2,3-a) (1, 3, 5)triazin-5-yl-amino]ethyl]-phenol (ZM241385; 100 nM).	ZM 241385	263-271	integrin subunit alpha 4	Homo sapiens	14-19
14525968-8	2004	A suboptimal ATL146e concentration (1 nM) combined with the type IV phosphodiesterase inhibitor rolipram (100 nM) synergistically decreased stimulated CD49d expression by >50%.	ATL 146e	13-20	integrin subunit alpha 4	Homo sapiens	151-156
14525968-8	2004	A suboptimal ATL146e concentration (1 nM) combined with the type IV phosphodiesterase inhibitor rolipram (100 nM) synergistically decreased stimulated CD49d expression by >50%.	Rolipram	96-104	integrin subunit alpha 4	Homo sapiens	151-156
14525968-9	2004	The cyclic adenosine monophosphate (cAMP)-dependent kinase [protein kinase A (PKA)] inhibitor H-89 (10 microM) reversed the effect of ATL146e on stimulated CD49d expression.	Cyclic AMP	4-34	integrin subunit alpha 4	Homo sapiens	156-161
14525968-9	2004	The cyclic adenosine monophosphate (cAMP)-dependent kinase [protein kinase A (PKA)] inhibitor H-89 (10 microM) reversed the effect of ATL146e on stimulated CD49d expression.	Cyclic AMP	36-40	integrin subunit alpha 4	Homo sapiens	156-161
14525968-9	2004	The cyclic adenosine monophosphate (cAMP)-dependent kinase [protein kinase A (PKA)] inhibitor H-89 (10 microM) reversed the effect of ATL146e on stimulated CD49d expression.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	94-98	integrin subunit alpha 4	Homo sapiens	156-161
14525968-10	2004	Other means of increasing cAMP in neutrophils also decreased stimulated CD49d expression.	Cyclic AMP	26-30	integrin subunit alpha 4	Homo sapiens	72-77
14525968-11	2004	We conclude that adenosine binding to A(2A)AR counteracts stimulation of neutrophil CD49d integrin expression and neutrophil binding to VCAM-1 via a cAMP/PKA-mediated pathway.	Adenosine	17-26	integrin subunit alpha 4	Homo sapiens	84-89
14657342-0	2003	Redox regulation of surface protein thiols: identification of integrin alpha-4 as a molecular target by using redox proteomics.	Sulfhydryl Compounds	36-42	integrin subunit alpha 4	Homo sapiens	62-78
14657342-7	2003	NAC pretreatment augmented integrin alpha-4-dependent fibronectin adhesion and aggregation of Jurkat cells without changing its expression by fluorescence-activated cell sorter, suggesting that reduction of surface disulfides can affect proteins function.	Acetylcysteine	0-3	integrin subunit alpha 4	Homo sapiens	27-43
14657342-7	2003	NAC pretreatment augmented integrin alpha-4-dependent fibronectin adhesion and aggregation of Jurkat cells without changing its expression by fluorescence-activated cell sorter, suggesting that reduction of surface disulfides can affect proteins function.	Disulfides	215-225	integrin subunit alpha 4	Homo sapiens	27-43
17101475-7	2006	Furthermore, the expression of CD44 and CD49d, which are of major importance in leukocyte extravasation, was even increased in DCP-treated as compared to AA patient infiltrates.	diphenylcyclopropenone	127-130	integrin subunit alpha 4	Homo sapiens	40-45
15895374-11	2005	Among the adhesion molecules, CD106, CD54, CD49d, and CD40, which were strongly expressed at baseline, showed a statistically significant reduction compared with controls after exposure to ZOL.	Zoledronic Acid	189-192	integrin subunit alpha 4	Homo sapiens	43-48
12047434-10	2002	Of the cluster designations tested, CD29, CD49d, CD51 and CD61 were strongly expressed on HBMMC.	hbmmc	90-95	integrin subunit alpha 4	Homo sapiens	42-47
12584220-7	2003	In contrast, they markedly differed in adhesion molecule expression, as LPPC showed higher levels of CD44 and CD21 and were alpha 4 beta 7(+) whereas BMPC lacked this integrin and expressed higher levels of CD49d and CD31.	Dimethylol-p-kresol	150-154	integrin subunit alpha 4	Homo sapiens	207-212
12527821-14	2002	At the molecular level, NAAGA inhibited histamine-induced expression of CD11b (P=0.0004) and CD49d (P=0.0045) on granulocytes.	isospaglumic acid	24-29	integrin subunit alpha 4	Homo sapiens	93-98
12527821-14	2002	At the molecular level, NAAGA inhibited histamine-induced expression of CD11b (P=0.0004) and CD49d (P=0.0045) on granulocytes.	Histamine	40-49	integrin subunit alpha 4	Homo sapiens	93-98
11342615-5	2001	Histamine also transiently up-regulates the expression of the costimulatory and accessory molecules, CD40, CD49d, CD54, CD80, and MHC class II.	Histamine	0-9	integrin subunit alpha 4	Homo sapiens	107-112
11877084-5	2001	RESULTS: The expression of CD(11a), CD(18), CD(49d), CD(54), CD(58) and CD(62L) of mobilized peripheral blood CD(34)(+) cells was lower than that of bone marrow ones, especially for CD(49d) and CD(62L).	Cadmium	27-29	integrin subunit alpha 4	Homo sapiens	182-188
11877084-6	2001	Similar to mobilized peripheral blood CD(34)(+) cells, cord blood CD(34)(+) cells also showed a lower expression of CD(11a), CD(18), CD(44), CD(49d), CD(62L) than that of bone marrow ones, especially for CD(62L), but expression of CD(54) was higher than that of bone marrow and mobilized peripheral blood CD(34)(+) cells.	Cadmium	66-68	integrin subunit alpha 4	Homo sapiens	141-147
11877084-6	2001	Similar to mobilized peripheral blood CD(34)(+) cells, cord blood CD(34)(+) cells also showed a lower expression of CD(11a), CD(18), CD(44), CD(49d), CD(62L) than that of bone marrow ones, especially for CD(62L), but expression of CD(54) was higher than that of bone marrow and mobilized peripheral blood CD(34)(+) cells.	Cadmium	66-68	integrin subunit alpha 4	Homo sapiens	141-147
11877084-6	2001	Similar to mobilized peripheral blood CD(34)(+) cells, cord blood CD(34)(+) cells also showed a lower expression of CD(11a), CD(18), CD(44), CD(49d), CD(62L) than that of bone marrow ones, especially for CD(62L), but expression of CD(54) was higher than that of bone marrow and mobilized peripheral blood CD(34)(+) cells.	Cadmium	66-68	integrin subunit alpha 4	Homo sapiens	141-147
10686583-1	2000	[(3)H]-Arachidonic acid-labelled rat T lymphocytes released radioactivity extracellularly when stimulated by the calcium ionophore A23187 or by monoclonal antibodies to some cell surface structures (CD2, CD5, CD11a, CD18, CD54, T-cell receptor) but not to others (CD49d, CD62L); release was greater with the calcium ionophore.	Tritium	1-5	integrin subunit alpha 4	Homo sapiens	264-269
11174197-9	2001	At 14 weeks of culture, more mature CHMCs expressed CD11b, CD11c, CD29, CD49b, CD49c, CD49d, CD49e, CD51, CD61, and CD54 and weakly expressed CD18 and CD11a.	chmcs	36-41	integrin subunit alpha 4	Homo sapiens	86-91
11953028-0	2001	Low oxygen tension and autologous plasma enhance T-cell proliferation and CD49d expression density in serum-free media.	Oxygen	4-10	integrin subunit alpha 4	Homo sapiens	74-79
11035069-7	2000	CD49d integrin expression was dependent on cell maturation, as its induction was abrogated by N:-acetylcysteine, which inhibits NF-kappaB activation and the functional and phenotypic maturation of MDDC.	Acetylcysteine	94-111	integrin subunit alpha 4	Homo sapiens	0-5
11035069-8	2000	Moreover, CD49d integrin up-regulation and MDDC maturation were prevented by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase, but were almost unaffected by the mitogen-activated protein/extracellular signal-related kinase kinase 1/2 inhibitor PD98059.	SB 203580	77-85	integrin subunit alpha 4	Homo sapiens	10-15
11035069-8	2000	Moreover, CD49d integrin up-regulation and MDDC maturation were prevented by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase, but were almost unaffected by the mitogen-activated protein/extracellular signal-related kinase kinase 1/2 inhibitor PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	266-273	integrin subunit alpha 4	Homo sapiens	10-15
10939719-4	2000	As a biological function exerted by this antigen, it was of great interest that immobilized mNI-11 directly and rapidly enhanced the spread formation of HUVECs, whereas MAbs binding other adhesion-associated antigens such as mNI-58A (anti-CD11a), L130 (anti-CD18), L133.1 (anti-CD31), L178 (anti-CD44), L25.3 (anti-CD49d), or LB-2 (anti-CD54) did not carry such activity under the same conditions.	mni-11	92-98	integrin subunit alpha 4	Homo sapiens	315-320
10939719-4	2000	As a biological function exerted by this antigen, it was of great interest that immobilized mNI-11 directly and rapidly enhanced the spread formation of HUVECs, whereas MAbs binding other adhesion-associated antigens such as mNI-58A (anti-CD11a), L130 (anti-CD18), L133.1 (anti-CD31), L178 (anti-CD44), L25.3 (anti-CD49d), or LB-2 (anti-CD54) did not carry such activity under the same conditions.	N-{[(2r,3r,4r,5r)-3,4-Dihydroxy-5-(Hydroxymethyl)pyrrolidin-2-Yl]methyl}-4-(Dimethylamino)benzamide	92-95	integrin subunit alpha 4	Homo sapiens	315-320
10837366-1	2000	In vitro incubation of mouse blood eosinophils with dexamethasone (DEX) resulted in concentration- and time-dependent reduction in CD11b and CD49d cell-surface expression as detected by flow cytometry.	Dexamethasone	52-65	integrin subunit alpha 4	Homo sapiens	141-146
10837366-1	2000	In vitro incubation of mouse blood eosinophils with dexamethasone (DEX) resulted in concentration- and time-dependent reduction in CD11b and CD49d cell-surface expression as detected by flow cytometry.	Dexamethasone	67-70	integrin subunit alpha 4	Homo sapiens	141-146
10837366-4	2000	Budesonide, hydrocortisone, and prednisolone, but not the sex steroids testosterone and progesterone, reduced CD11b and CD49d cell-surface expression to a similar extent.	Budesonide	0-10	integrin subunit alpha 4	Homo sapiens	120-125
10837366-4	2000	Budesonide, hydrocortisone, and prednisolone, but not the sex steroids testosterone and progesterone, reduced CD11b and CD49d cell-surface expression to a similar extent.	Hydrocortisone	12-26	integrin subunit alpha 4	Homo sapiens	120-125
10837366-4	2000	Budesonide, hydrocortisone, and prednisolone, but not the sex steroids testosterone and progesterone, reduced CD11b and CD49d cell-surface expression to a similar extent.	Prednisolone	32-44	integrin subunit alpha 4	Homo sapiens	120-125
10686583-1	2000	[(3)H]-Arachidonic acid-labelled rat T lymphocytes released radioactivity extracellularly when stimulated by the calcium ionophore A23187 or by monoclonal antibodies to some cell surface structures (CD2, CD5, CD11a, CD18, CD54, T-cell receptor) but not to others (CD49d, CD62L); release was greater with the calcium ionophore.	Arachidonic Acid	7-23	integrin subunit alpha 4	Homo sapiens	264-269
10329822-8	1999	RESULTS: We found that DTT decreased the expression of CD11a and CD49d on lymphocytes and eosinophils.	Dithiothreitol	23-26	integrin subunit alpha 4	Homo sapiens	65-70
9708449-12	1998	The strongest association to the proliferative status was observed for CD49d, which was coexpressed by 85.9% +/-2.6% (BM) or 90.8%+/-2.5% (LP) of CD34+/S/G2M cells, whereas a distinct CD34+/CD49d-/S/G2M population could not be detected.	leucylproline	139-141	integrin subunit alpha 4	Homo sapiens	71-76
10410379-3	1999	Treatment of Ad-HL60 cells with 1 microM PGE2 resulted in a decrease in the rate of cell proliferation (cell numbers were approximately 23% of control values after 72 h treatment), a change in expression of leukocyte surface antigens (decreased CD13 and CD14, increased CD11b and CD49d expression), an increase in the synthesis of 24,25-dihydroxyvitamin D3 from substrate 25-hydroxyvitamin D3 (control 5.76 +/- 0.17, 72 h PGE2-treated cells 12.10 +/- 1.90 pmol/h/10(6) cells), and an increase in receptors for the active metabolite of vitamin D, 1 alpha,25-dihydroxyvitamin D3, from 3910 to 11285 receptors per cell in control and 7-day treated cells, respectively.	Dinoprostone	41-45	integrin subunit alpha 4	Homo sapiens	280-285
9744992-7	1998	The overnight cultivation of the peripheral blood mononuclear cells in the presence of alendronate resulted in an increased surface expression of CD54 (intercellular adhesion molecule-1, ICAM-1) in both CD14(+) and CD3(+) cells; in CD14(+) cells also the expression of CD49d (alpha4 subunit of late activation antigen-4, VLA-4) increased after alendronate treatment.	Alendronate	87-98	integrin subunit alpha 4	Homo sapiens	269-274
9209507-0	1997	Clustering the adhesion molecules VLA-4 (CD49d/CD29) in Jurkat T cells or VCAM-1 (CD106) in endothelial (ECV 304) cells activates the phosphoinositide pathway and triggers Ca2+ mobilization.	Phosphatidylinositols	134-150	integrin subunit alpha 4	Homo sapiens	41-46
8389585-4	1993	IA-3 and IA-5 are lucanthone analogs bearing a methyl group at position 4, whereas IA-4 and IA-6 are hycanthone analogs bearing a hydroxymethyl group.	Hycanthone	101-111	integrin subunit alpha 4	Homo sapiens	83-87
8534491-3	1996	Crosslinking either CD29 or CD49d caused a significant histamine release (HR) from the basophils of most asthmatic donors (10 of 14 for CD49d and 7 of 10 for CD29) (HR = 21 +/- 5%, n = 10, P < 0.005 for CD29 and HR = 19 +/- 4%, n = 14, P < 0.01 for CD49d) yet failed to initiate HR from the basophils of non-atopic and atopic donors (HR was 1 +/- 0.5% for CD29 and 1 +/- 0.5% for CD49d, n = 10, P = NS).	Histamine	55-64	integrin subunit alpha 4	Homo sapiens	28-33
8534491-3	1996	Crosslinking either CD29 or CD49d caused a significant histamine release (HR) from the basophils of most asthmatic donors (10 of 14 for CD49d and 7 of 10 for CD29) (HR = 21 +/- 5%, n = 10, P < 0.005 for CD29 and HR = 19 +/- 4%, n = 14, P < 0.01 for CD49d) yet failed to initiate HR from the basophils of non-atopic and atopic donors (HR was 1 +/- 0.5% for CD29 and 1 +/- 0.5% for CD49d, n = 10, P = NS).	Histamine	55-64	integrin subunit alpha 4	Homo sapiens	136-141
8534491-3	1996	Crosslinking either CD29 or CD49d caused a significant histamine release (HR) from the basophils of most asthmatic donors (10 of 14 for CD49d and 7 of 10 for CD29) (HR = 21 +/- 5%, n = 10, P < 0.005 for CD29 and HR = 19 +/- 4%, n = 14, P < 0.01 for CD49d) yet failed to initiate HR from the basophils of non-atopic and atopic donors (HR was 1 +/- 0.5% for CD29 and 1 +/- 0.5% for CD49d, n = 10, P = NS).	Histamine	55-64	integrin subunit alpha 4	Homo sapiens	136-141
7514154-1	1994	The lectin GS I-A4 binds to terminal alpha-N-acetylgalactosaminyl (GalNAc) groups (which include the Tn antigen), but not to the closely related tumor-associated epitope, sialylated Tn antigen.	alpha-n-acetylgalactosaminyl	37-65	integrin subunit alpha 4	Homo sapiens	14-18
7514154-1	1994	The lectin GS I-A4 binds to terminal alpha-N-acetylgalactosaminyl (GalNAc) groups (which include the Tn antigen), but not to the closely related tumor-associated epitope, sialylated Tn antigen.	N-acetylgalactosaminuronic acid	67-73	integrin subunit alpha 4	Homo sapiens	14-18
7514154-4	1994	Glycoconjugates bound by GS I-A4 were observed on the surface membranes of 2 human colon cancer cell lines, LS174t and SW1116, when fluorescein isothiocyanate (FITC)-conjugated GS I-A4 was used.	Fluorescein-5-isothiocyanate	132-158	integrin subunit alpha 4	Homo sapiens	28-32
7514154-4	1994	Glycoconjugates bound by GS I-A4 were observed on the surface membranes of 2 human colon cancer cell lines, LS174t and SW1116, when fluorescein isothiocyanate (FITC)-conjugated GS I-A4 was used.	Fluorescein-5-isothiocyanate	132-158	integrin subunit alpha 4	Homo sapiens	180-184
7514154-4	1994	Glycoconjugates bound by GS I-A4 were observed on the surface membranes of 2 human colon cancer cell lines, LS174t and SW1116, when fluorescein isothiocyanate (FITC)-conjugated GS I-A4 was used.	Fluorescein-5-isothiocyanate	160-164	integrin subunit alpha 4	Homo sapiens	28-32
7514154-8	1994	Four mM GalNAc specifically inhibited the cytotoxic effect of GS I-A4 (p < 0.001), whereas 4mM N-acetylglucosamine (GlcNAc) had no effect.	N-acetylgalactosaminuronic acid	8-14	integrin subunit alpha 4	Homo sapiens	65-69
7516993-12	1994	Other markers, such as the alpha chains of the beta 1 integrins CD49b (VLA alpha 2) and CD49d (VLA alpha 4) showed contrasting reactions to the Thd-treatment.	Thalidomide	144-147	integrin subunit alpha 4	Homo sapiens	88-93
18472871-1	1997	Overnight incubation of human eosinophils (Eos) with the glucocorticoid hormone dexamethasone (DEX; 0.1 microM) resulted in lower expression of the CD11b, but not CD49d, antigen on their plasma membrane, as assessed by flow cytometry.	Dexamethasone	80-93	integrin subunit alpha 4	Homo sapiens	163-168
8611173-0	1996	Integrin alpha 4 cysteines 278 and 717 modulate VLA-4 ligand binding and also contribute to alpha 4/180 formation.	Cysteine	17-26	integrin subunit alpha 4	Homo sapiens	0-16
8611173-1	1996	Here we describe experiments in which we mutated four of the six integrin alpha 4 subunit cysteine residues that are not present in most other integrin alpha subunits that lack an I domain.	Cysteine	90-98	integrin subunit alpha 4	Homo sapiens	65-81
8611173-2	1996	In four different types of ligand binding assay we found that optimal integrin alpha 4 beta 1 and/or to CS1 peptide required the presence of both alpha 4 Cys 278 and Cys 717.	Cysteine	154-157	integrin subunit alpha 4	Homo sapiens	70-86
8611173-2	1996	In four different types of ligand binding assay we found that optimal integrin alpha 4 beta 1 and/or to CS1 peptide required the presence of both alpha 4 Cys 278 and Cys 717.	Cysteine	166-169	integrin subunit alpha 4	Homo sapiens	70-86
8534491-3	1996	Crosslinking either CD29 or CD49d caused a significant histamine release (HR) from the basophils of most asthmatic donors (10 of 14 for CD49d and 7 of 10 for CD29) (HR = 21 +/- 5%, n = 10, P < 0.005 for CD29 and HR = 19 +/- 4%, n = 14, P < 0.01 for CD49d) yet failed to initiate HR from the basophils of non-atopic and atopic donors (HR was 1 +/- 0.5% for CD29 and 1 +/- 0.5% for CD49d, n = 10, P = NS).	Histamine	55-64	integrin subunit alpha 4	Homo sapiens	136-141
8534491-8	1996	The tyrosine kinase inhibitor, genistein, significantly reduced CD29- and CD49d-induced HR (inhibition = 83 +/- 7% for CD29 and 77 +/- 6% for CD49d, n > or = 5, P < 0.05).	Genistein	31-40	integrin subunit alpha 4	Homo sapiens	74-79
8534491-8	1996	The tyrosine kinase inhibitor, genistein, significantly reduced CD29- and CD49d-induced HR (inhibition = 83 +/- 7% for CD29 and 77 +/- 6% for CD49d, n > or = 5, P < 0.05).	Genistein	31-40	integrin subunit alpha 4	Homo sapiens	142-147
8534491-9	1996	A second tyrosine kinase inhibitor, piceatannol, also significantly reduced both CD29- and CD49d-induced HR (inhibition was 62 +/- 19% for CD29 and 56 +/- 14% for CD49d, n = 7, P < or = 0.05).	3,3',4,5'-tetrahydroxystilbene	36-47	integrin subunit alpha 4	Homo sapiens	91-96
8534491-9	1996	A second tyrosine kinase inhibitor, piceatannol, also significantly reduced both CD29- and CD49d-induced HR (inhibition was 62 +/- 19% for CD29 and 56 +/- 14% for CD49d, n = 7, P < or = 0.05).	3,3',4,5'-tetrahydroxystilbene	36-47	integrin subunit alpha 4	Homo sapiens	163-168
8534491-11	1996	Both CD29 and CD49d clustering significantly inhibited anti-IgE-induced histamine release from the human basophil.	Histamine	72-81	integrin subunit alpha 4	Homo sapiens	14-19
7544372-4	1995	Tyrosine phosphorylation of several stromal cell proteins was stimulated within 5 to 10 min of contact with either CD49d-expressing or CD49d-deficient RAMOS.	Tyrosine	0-8	integrin subunit alpha 4	Homo sapiens	115-120
7544372-4	1995	Tyrosine phosphorylation of several stromal cell proteins was stimulated within 5 to 10 min of contact with either CD49d-expressing or CD49d-deficient RAMOS.	Tyrosine	0-8	integrin subunit alpha 4	Homo sapiens	135-140
7542062-6	1995	Incubating the basophils of these asthmatic donors with a synthetic RGD peptide significantly reduced CD29- and CD49d-induced histamine release.	Histamine	126-135	integrin subunit alpha 4	Homo sapiens	112-117
7542062-8	1995	The tyrosine kinase inhibitors, genistein and piceatannol, completely ablated CD29- and CD49d-induced degranulation.	Genistein	32-41	integrin subunit alpha 4	Homo sapiens	88-93
7542062-8	1995	The tyrosine kinase inhibitors, genistein and piceatannol, completely ablated CD29- and CD49d-induced degranulation.	3,3',4,5'-tetrahydroxystilbene	46-57	integrin subunit alpha 4	Homo sapiens	88-93
1435868-6	1992	Covalent binding of tritiated HC to macromolecules could be inhibited by cold HC, oxamniquine or IA-4, while none of the in vitro ineffective analogs, like lucanthone, UK-3883 or 4-desmethyl lucanthone, were inhibitory.	Hycanthone	30-32	integrin subunit alpha 4	Homo sapiens	97-101
34934426-5	2022	In the present study, the use of a novel non-peptidic small molecule integrin alpha4 antagonist, AVA4746, as a potential new approach to combat drug-resistant B-ALL was explored.	UNII-7M2IM94F1S	97-104	integrin subunit alpha 4	Homo sapiens	69-84
29301866-0	2018	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.	ibrutinib	59-68	integrin subunit alpha 4	Homo sapiens	44-49
29301866-5	2018	Clinically, in three independent ibrutinib-treated CLL cohorts, CD49d expression identifies cases with reduced lymphocytosis and inferior nodal response and behaves as independent predictor of shorter progression-free survival, suggesting the retention of CD49d-expressing CLL cells in tissue sites via activated VLA-4.	ibrutinib	33-42	integrin subunit alpha 4	Homo sapiens	64-69
29301866-5	2018	Clinically, in three independent ibrutinib-treated CLL cohorts, CD49d expression identifies cases with reduced lymphocytosis and inferior nodal response and behaves as independent predictor of shorter progression-free survival, suggesting the retention of CD49d-expressing CLL cells in tissue sites via activated VLA-4.	ibrutinib	33-42	integrin subunit alpha 4	Homo sapiens	256-261
18268283-5	2008	We report on the downregulation of VLA-4/CD49d for various acute myelogenous leukemia cells lines, on primary cells from patients with acute myelogenous leukemia, and on hematopoietic stem cells and peripheral blood mononuclear cells from healthy donors on treatment with the histone deacetylase inhibitors suberoylanilide hydroxamic acid and valproic acid, which is associated with decreased adhesion to mesenchymal stromal cells.	Vorinostat	307-338	integrin subunit alpha 4	Homo sapiens	41-46
18268283-5	2008	We report on the downregulation of VLA-4/CD49d for various acute myelogenous leukemia cells lines, on primary cells from patients with acute myelogenous leukemia, and on hematopoietic stem cells and peripheral blood mononuclear cells from healthy donors on treatment with the histone deacetylase inhibitors suberoylanilide hydroxamic acid and valproic acid, which is associated with decreased adhesion to mesenchymal stromal cells.	Valproic Acid	343-356	integrin subunit alpha 4	Homo sapiens	41-46
35284127-2	2022	It has been suggested that the cytosine-phosphate-guanine (CpG) island of itga4 is highly methylated in colorectal adenoma cell lines AA/C1, Vaco 235 and so on.	cytosine-phosphate-guanine	31-57	integrin subunit alpha 4	Homo sapiens	74-79
34247018-9	2021	Suppressive potency of CD49d- Treg cells to inhibit Tconv cells proliferation was diminished, and inversely related to fasting plasma glucose and hemoglobin A1c in the patients.	Glucose	134-141	integrin subunit alpha 4	Homo sapiens	23-28
34013974-10	2021	CD49d-negative CLL cases were more sensitive to lenalidomide treatment.	Lenalidomide	48-60	integrin subunit alpha 4	Homo sapiens	0-5
6165888-6	1981	The effects of a hycanthone analog, IA-4, were largely comparable to the effects of the parent compound.	Hycanthone	17-27	integrin subunit alpha 4	Homo sapiens	36-40
33922540-4	2021	The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients.	Fingolimod Hydrochloride	139-149	integrin subunit alpha 4	Homo sapiens	62-67
33922540-4	2021	The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients.	Dimethyl Fumarate	154-171	integrin subunit alpha 4	Homo sapiens	62-67
33922540-4	2021	The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients.	Cladribine	182-192	integrin subunit alpha 4	Homo sapiens	62-67
33922540-4	2021	The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients.	Dimethyl Fumarate	208-225	integrin subunit alpha 4	Homo sapiens	62-67
33869896-5	2021	Results showed that exposure to boscalid alone has no significant effect on cell junction genes, however, co-exposure to boscalid and TiO2 significantly regulated expression of cell-matrix junction focal adhesion-related genes, e.g., downregulating Cav1 (- 1.39-fold, p<0.05), upregulating Cav3 (+ 3.30-fold, p<0.01) and Itga4 (+ 3.30-fold, p<0.05).	titanium dioxide	134-138	integrin subunit alpha 4	Homo sapiens	321-326
33869896-6	2021	Similarly, co-exposure to boscalid and SiO2 significantly downregulated multiple cell-cell junction genes, including tight junction genes (Cldn1, Cldn11, Cldn16, Cldn18, and Jam3), adherens junction genes (Notch1, Notch3, Pvrl1) and gap junction genes (Gja3 and Gjb2), as well as cell-matrix junction focal adhesion genes (Itga4, Itga6, Itga7).	2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide	26-34	integrin subunit alpha 4	Homo sapiens	323-328
33869896-6	2021	Similarly, co-exposure to boscalid and SiO2 significantly downregulated multiple cell-cell junction genes, including tight junction genes (Cldn1, Cldn11, Cldn16, Cldn18, and Jam3), adherens junction genes (Notch1, Notch3, Pvrl1) and gap junction genes (Gja3 and Gjb2), as well as cell-matrix junction focal adhesion genes (Itga4, Itga6, Itga7).	Silicon Dioxide	39-43	integrin subunit alpha 4	Homo sapiens	323-328
32236695-7	2020	Unexpectedly, the whole blood-based protocol that uses additional alpha-CD49d co-stimulation was less susceptible to CsA and prednisolone despite prolonged drug exposure in the test tube.	Cyclosporine	117-120	integrin subunit alpha 4	Homo sapiens	72-77
32236695-7	2020	Unexpectedly, the whole blood-based protocol that uses additional alpha-CD49d co-stimulation was less susceptible to CsA and prednisolone despite prolonged drug exposure in the test tube.	Prednisolone	125-137	integrin subunit alpha 4	Homo sapiens	72-77
32306097-11	2020	CD49d+ PAGs were reduced by 30-40% and were functionally impaired in diabetic vs control individuals.	pags	7-11	integrin subunit alpha 4	Homo sapiens	0-5
33214335-11	2020	Thus, bortezomib may have potential clinical applications in the treatment of CD49d- and CD49e-mediated CAM-DR in BL patients.	Bortezomib	6-16	integrin subunit alpha 4	Homo sapiens	78-83
33438631-2	2020	Flow cytometric analysis showed that both CD105 and CD49d positive hASCs increased rapidly with passage number on the lead polymers, while quantitative PCR analysis showed that the substrate synthesized from methacryloxyethyltrimethyl ammonium chloride, N,N-diethylaminoethyl methacrylate and cyclohexyl methacrylate enhanced chondrogenesis and osteogenensis some 4 and 25 times respectively in terms of the expression of SOX9 and ALP in differentiated stem cells.	lead polymers	118-131	integrin subunit alpha 4	Homo sapiens	52-57
30417790-0	2020	Efficacy of beta-D-mannuronic acid [M2000] on pro-apoptotic process and inflammatory related molecules NFkB, IL-8 and Cd49d using healthy donor PBMC.	mannuronic acid	12-34	integrin subunit alpha 4	Homo sapiens	118-123
30417790-1	2020	This investigation evaluates the pro-apoptotic and anti-inflammatory effects of beta-D-mannuronic acid [M2000] compared to diclofenac, based on gene expression involved in apoptosis and inflammation process [including Bcl2, NFkappaB, IL-8 and Cd49d] in peripheral blood mononuclear cells [PBMCs] of healthy donors under exvivo conditions.	mannuronic acid	80-102	integrin subunit alpha 4	Homo sapiens	243-248
31506448-0	2019	Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides.	Oligonucleotides	75-91	integrin subunit alpha 4	Homo sapiens	13-29
31506448-2	2019	Our laboratory focuses on developing therapeutic splice modulating antisense oligonucleotides to treat diseases potentially amendable to intervention during pre-mRNA processing, and here we report the use of oligomers to down-regulate integrin alpha 4 protein levels.	Oligonucleotides	77-93	integrin subunit alpha 4	Homo sapiens	235-251
31506448-3	2019	Over one hundred antisense oligonucleotides were designed to induce skipping of individual exons of the ITGA4 transcript and thereby reducing protein expression.	Oligonucleotides	27-43	integrin subunit alpha 4	Homo sapiens	104-109
32860851-0	2020	Integrin alpha4 up-regulation activates the hedgehog pathway to promote arsenic and benzo[alpha]pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis.	Arsenic	72-79	integrin subunit alpha 4	Homo sapiens	0-15
32860851-0	2020	Integrin alpha4 up-regulation activates the hedgehog pathway to promote arsenic and benzo[alpha]pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis.	Benzo[alpha]pyrene	84-102	integrin subunit alpha 4	Homo sapiens	0-15
32860851-4	2020	It was found that integrin alpha4 (ITGA4) expression levels are significantly up-regulated and the Hedgehog pathway is highly activated in arsenic plus BaP co-exposure-transformed human bronchial epithelial cells.	Arsenic	139-146	integrin subunit alpha 4	Homo sapiens	18-33
32860851-4	2020	It was found that integrin alpha4 (ITGA4) expression levels are significantly up-regulated and the Hedgehog pathway is highly activated in arsenic plus BaP co-exposure-transformed human bronchial epithelial cells.	Arsenic	139-146	integrin subunit alpha 4	Homo sapiens	35-40
32860851-4	2020	It was found that integrin alpha4 (ITGA4) expression levels are significantly up-regulated and the Hedgehog pathway is highly activated in arsenic plus BaP co-exposure-transformed human bronchial epithelial cells.	benzylaminopurine	152-155	integrin subunit alpha 4	Homo sapiens	18-33
32860851-4	2020	It was found that integrin alpha4 (ITGA4) expression levels are significantly up-regulated and the Hedgehog pathway is highly activated in arsenic plus BaP co-exposure-transformed human bronchial epithelial cells.	benzylaminopurine	152-155	integrin subunit alpha 4	Homo sapiens	35-40
32860851-8	2020	These findings indicate that ITGA4 up-regulation activates the Hedgehog pathway to enhance the CSC-like property and tumorigenicity of arsenic and BaP co-exposure-transformed cells, offering new mechanistic insight for the synergistic carcinogenic effect of arsenic and BaP co-exposure.	Arsenic	135-142	integrin subunit alpha 4	Homo sapiens	29-34
32860851-8	2020	These findings indicate that ITGA4 up-regulation activates the Hedgehog pathway to enhance the CSC-like property and tumorigenicity of arsenic and BaP co-exposure-transformed cells, offering new mechanistic insight for the synergistic carcinogenic effect of arsenic and BaP co-exposure.	benzylaminopurine	147-150	integrin subunit alpha 4	Homo sapiens	29-34
32860851-8	2020	These findings indicate that ITGA4 up-regulation activates the Hedgehog pathway to enhance the CSC-like property and tumorigenicity of arsenic and BaP co-exposure-transformed cells, offering new mechanistic insight for the synergistic carcinogenic effect of arsenic and BaP co-exposure.	Arsenic	258-265	integrin subunit alpha 4	Homo sapiens	29-34
32860851-8	2020	These findings indicate that ITGA4 up-regulation activates the Hedgehog pathway to enhance the CSC-like property and tumorigenicity of arsenic and BaP co-exposure-transformed cells, offering new mechanistic insight for the synergistic carcinogenic effect of arsenic and BaP co-exposure.	benzylaminopurine	270-273	integrin subunit alpha 4	Homo sapiens	29-34